Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6044044 | 1.00 | SLC6A3 (0.42) | SLC6A3SLC6A2SLC6A4ADRA2AADRA2B | |
| SCHEMBL6042548 | 1.00 | SLC6A3 (0.42) | SLC6A3SLC6A2SLC6A4ADRA2AADRA2B | |
| SCHEMBL3173810 | 0.71 | HIF1A (0.64) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL10326686 | 0.71 | SLC6A4 (0.43) | SLC6A3SLC6A2SLC6A4ADRA2AADRA2B | |
| SCHEMBL10326897 | 0.71 | SLC6A4 (0.43) | SLC6A3SLC6A2SLC6A4ADRA2AADRA2B | |
| SCHEMBL10326262 | 0.71 | SLC6A4 (0.43) | SLC6A3SLC6A2SLC6A4ADRA2AADRA2B | |
| SCHEMBL11672373 | 0.69 | UGT2B7 (0.61) | SLC6A3SLC6A2SLC6A4ADRA2AADRA2B | |
| SCHEMBL7055482 | 0.69 | UGT2B7 (0.61) | SLC6A3SLC6A2SLC6A4ADRA2AADRA2B | |
| SCHEMBL2956980 | 0.69 | UGT2B7 (0.61) | SLC6A3SLC6A2SLC6A4ADRA2AADRA2B | |
| SCHEMBL30036151 | 0.69 | SLC6A3 (0.73) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | SLC6A3 2921/4885SLC6A2 3109/4885SLC6A4 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.